Sophia Genetics reported first-quarter growth driven by expanded use of its Sophia DDM platform, recording a 22% revenue increase. The company also highlighted platform activity with a record 108,000 analyses run during the quarter. Sophia Genetics said the analyses on the Sophia DDM platform represented 16% year-over-year growth and provided an execution signal on scaling precision medicine workflows. While the financial details in the snapshot were limited, the focus on volume and platform throughput indicates Sophia’s strategy remains centered on increasing adoption and operational cadence rather than only product introductions. For precision medicine operators, this kind of platform volume growth can translate into stronger unit economics and deeper payer/provider integration over time.